Canadian application, no grantCanada
Treatment of obesity and essential hypertension and related disorders
CA 2020786 A1 · Owner: Leighton, Brendan · Inventors: Cooper, Garth J.S.; Leighton, Brendan
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 10, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 10, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 10, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 10, 1990
GrantedNo grant recorded
Term endedJuly 10, 2010
Patent numberCA 2020786 A1
Classification (IPC)A61K39/39 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.